- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02264756
Improving Antibiotic Use in Hospitalized Patients With Pneumonia (CAPASP)
Evaluating the Effectiveness of an Antimicrobial Stewardship Program on Reducing the Length of Stay of Immune-competent Adult Patients Admitted to a Hospital Ward With a Diagnosis of Community-acquired Pneumonia
Study Overview
Detailed Description
In immune-competent adult patients admitted to a hospital ward with a diagnosis of community-acquired pneumonia, does a multi-faceted ASP utilizing prospective chart audit and feedback compared with usual care reduce the LOS without increasing the risk of death or readmission at 30 days post-discharge from hospital? In Ontario, pneumonia is the leading cause of death from bacterial infections and accounts for over 18,000 years of life lost annually due to premature mortality. Pneumonia accounts for the majority of antibiotic utilization in both hospital and outpatient settings. Evidence-based guidelines for the diagnosis and management of pneumonia are available to physicians. Adherence to these evidence-based guidelines is associated with both reduced mortality and antibiotic utilization.
Antimicrobial stewardship is defined as any intervention that minimizes unwarranted variation in antimicrobial utilization from evidence-based best practice with the intent of improving patient safety and quality of care. Unwarranted refers to the absence of patient- or disease-specific reasons to justify practice variation from evidence-based practice standards. Antimicrobial stewardship can be operationalized in many different ways, but prospective audit and feedback (persuasive approach) and restricted antimicrobial prescribing policies (restrictive approach) appear to be the most efficacious interventions to achieve the goals of antimicrobial stewardship. Antimicrobial stewardship programs have demonstrated efficacy in improving antimicrobial prescribing and reducing rates of hospital-acquired infections. Antimicrobial stewardship programs directed to CAP patients have demonstrated reductions in mortality, but have failed to demonstrate reductions in length of stay.
All participants will be admitted patients to the Royal Victoria Regional Health Centre (RVRHC), a 319 bed community-based, university-affiliated, acute care hospital located in Barrie, Ontario, Canada.
All patients enrolled in the study will be admitted to one of four medical wards. All study patients will be admitted to a hospitalist service. Admission to any medical ward is controlled by bed allocation, a non-medical administrative service within the hospital responsible for patient flow and assigning patient care. Hospitalists are not assigned to any one specific medical ward, but provide care across all medical wards.
All eligible CAP who meet the ASP review criteria will be exposed to the ASP intervention. The ASP intervention (ASP-i) consists of a prospective chart audit and physician feedback (persuasive) approach . The ASP members who conduct all the audits and make recommendations consist of an infectious diseases-trained pharmacist (LM) and an infectious diseases trained physician (GD). All patients are reviewed by both members. The ASP intervention (ASP-i) recommendations are guided by the Infectious Diseases Society of America CAP guidelines and the Canadian Thoracic Society guidelines for the management of chronic obstructive pulmonary disease. The possible ASP-i recommendations are based on those recommended by the National Health Service in the United Kingdom and include the following:
i) No change to current care ii) Discontinue antibiotic(s) iii) Intravenous to oral conversion iv) Duration of therapy v) Dosing change vi) Narrow or broaden spectrum of therapy The ASP-i recommendations are not mutually exclusive. All recommendations are documented in the patient's electronic medical record and communicated directly to the attending physician by the ASP members.
This is a pragmatic controlled clinical study intended to measure the effectiveness of a 'real world' program. The ASP-i will be implemented in a modified stepped wedge design; baseline patient data will be collected for all enrolled patients on each of the medical wards for the first three months of the study, and then the ASP-i will be introduced to each medical ward in a non-randomized sequential fashion in two month intervals until all medical wards are exposed to the intervention.
The unit of analysis will be individual patients adjusted for potential clustering effects within hospital wards.
The primary outcome is length of hospital stay (LOS) measured in minutes from the documented time of admission to the documented time of discharge (or censoring). All patients will be administratively censored at 14 days after hospital admission if they have not been discharged home.
Enrollment of patients started on April 1, 2013. The study is expected to enroll patients until March 31, 2015. All consecutive patients that meet the inclusion criteria and have no exclusion criteria will be eligible for the intervention. The ASP-i intervention may be implemented anytime after 48 hours post-admission in those patients who meet the criteria for ASP review. All patients who have not experienced an outcome at 14 days after admission will be censored from the study. Patients who die or are transferred from the ward (to the intensive care unit or other hospital) will also be censored. Patients who are discharged from hospital and are not censored will be contacted at 30 days post-discharge to determine their adherence with antibiotic prescription (if relevant), survival status and readmission status.
The sample size expected for the current study is 'fixed' and has been previously estimated to be between 400 to 500 CAP patients per calendar year. The accrual period will be 24 months. Assuming 70% of patients in the control arm will achieve the primary outcome of being discharged alive from hospital, and setting power = 0.8 and statistical significance (2-sided) α = 0.05, the detectable ASP-i effect size is estimated to be up to an approximately 20% reduction in length of stay.
An extended Cox regression analysis will be used to compare the primary and secondary outcomes between the control and intervention groups. Violations of the proportional hazards assumption for each covariate will be identified by using the method of Schoenfeld residuals. Results will be reported as hazard ratios with 95% confidence intervals. Time to ASP-i will be modeled as a time-variant covariate in the final model to account for any time-dependent bias.
Other variables known to be associated with the primary and secondary outcomes will also be included in the final model, and include; age, sex, charlson comorbidity index, CURB-65 score, time (days) to clinical resolution, and complications from pneumonia such as empyema. Fixed effects of wards on the outcomes will accounted for by including them as indicator variables in the final model. Maturation of ASP-i effect on outcomes over time will be adjusted by including a categorical time variable in the final model (time variable will be defined as 'quarter' from start of study). A dichotomous variable for acceptance or rejection of the ASP-i will be part of an interaction term with the control/intervention group variable to permit a per protocol analysis.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Ontario
-
Barrie, Ontario, Canada, L0L2L0
- Royal Victoria Regional Health Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- have a positive Febrile Respiratory Illness (FRI) screen on admission to hospital (http://www.health.gov.on.ca/fr/public/programs/emu/sars/reports/dir_122303_acute_care_nonoutbreak.pdf)
- diagnosed with pneumonia by the admitting physician (Acute exacerbations of chronic obstructive lung disease are considered within the definition of pneumonia for the purposes of this study as they are commonly treated with the same antimicrobial regimens as patients with pneumonia)
- admitted to a medical ward
Exclusion Criteria:
- hospitalized for ≥ 48 consecutive hours in the preceding 3 months
- receiving immunosuppressants [defined as ≥ 40 mg prednisone daily (or steroid equivalent) for ≥ 2 weeks preceding hospitalization OR any other immunosuppressant used for systemic illness OR to prevent transplant rejection]
- neutropenic [defined as a polymorphonuclear count ≤ 0.5 x 109 cells/L] from any cause
- immunocompromised [defined as having leukemia, lymphoma, HIV with CD4 cell count ≤ 200, splenectomy or on cytotoxic chemotherapy]
- admitted to high acuity units such as intensive care units
- require mechanical ventilation, either non-invasive or invasive
- have a life expectancy of ≤ 3 months (palliative)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Ward CAP
Adult immune-competent patients admitted to ward with clinical diagnosis of community-acquired pneumonia will be potentially exposed to ASP review
|
patients admitted to hospital with a diagnosis of community-acquired pneumonia will be reviewed by team members of antimicrobial stewardship program and subsequently feedback to attending physicians will be offered in the form of recommendations for antibiotic management
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hospital length of stay
Time Frame: Patients will be followed for 14 days from date of admission and if not discharged will be administratively censored
|
Time to discharge or censoring event
|
Patients will be followed for 14 days from date of admission and if not discharged will be administratively censored
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
30-day post-discharge mortality rate
Time Frame: 30 calendar days after hospital discharge
|
all cause mortality at 30 days post-discharge from hospital
|
30 calendar days after hospital discharge
|
30-day post-discharge readmission rate
Time Frame: 30 calendar days after hospital discharge
|
all cause readmission rate at 30 days post-discharge from hospital
|
30 calendar days after hospital discharge
|
Days of antimicrobial therapy
Time Frame: Total days of antimicrobial therapy for each antibiotic calculated from date of first administration on admission to hospital to date of discontinuation (or to date of censoring, whichever comes first) upto a maximum of 30 days post-discharge follow-up
|
Total days of antimicrobial therapy used per patient upto a maximum of 30-days post-discharge from hospital
|
Total days of antimicrobial therapy for each antibiotic calculated from date of first administration on admission to hospital to date of discontinuation (or to date of censoring, whichever comes first) upto a maximum of 30 days post-discharge follow-up
|
Duration of antimicrobial therapy
Time Frame: Total duration of all antibiotics administered starting from date of administration of first antibiotic to date of discontinuation of last antibiotic (or to date of censoring, whichever comes first) upto a maximum of 30 days post-discharge from hospital
|
Total duration of antimicrobial therapy per patient upto a maximum of 30-days post discharge from hospital
|
Total duration of all antibiotics administered starting from date of administration of first antibiotic to date of discontinuation of last antibiotic (or to date of censoring, whichever comes first) upto a maximum of 30 days post-discharge from hospital
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Giulio DiDiodato, MD, Royal Victoria Regional Health Centre
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAPASP2013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Venatorx Pharmaceuticals, Inc.Biomedical Advanced Research and Development AuthorityNot yet recruitingHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
Hannover Medical SchoolCharite University, Berlin, Germany; University of LeipzigUnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious OrganismsGermany
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired PneumoniaFrance
-
PfizerCompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
-
Arpida AGTerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
ShionogiCompletedHospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)Israel, Spain, United States, Belgium, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Japan, Latvia, Philippines, Puerto Rico, Russian Federation, Serbia, Taiwan, Ukraine
-
Hu YinanEnrolling by invitationSialic Acid | Superoxide Dismutase | Lipid PneumoniaChina
Clinical Trials on ASP review
-
University of ChicagoAsphelia PharmaceuticalsCompletedAllergic RhinitisUnited States
-
ASP HealthMayo ClinicNot yet recruitingLung Diseases | Lung Cancer
-
University of TorontoSinai Health SystemUnknownSore Throat | Acute Rhinosinusitis | Acute Bronchitis | Acute CystitisCanada
-
Rakuten Medical, Inc.National Cancer Institute (NCI); Shimadzu CorporationRecruitingHead and Neck Cancer | Squamous Cell Carcinoma of Head and NeckUnited States
-
The University of Hong KongUnknown
-
Iowa State UniversityCompletedIron-deficiency | Bioavailability | Anemia, Iron Deficiency | Absorption; Iron | Serum IronUnited States
-
Joke WuytsAssociation of Belgian Pharmacies (APB)Completed
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMalignant Central Nervous System Neoplasm | Malignant Skull Base NeoplasmUnited States
-
Hospital Pablo Tobón UribeCompletedUrinary Tract Infections | Urinary Tract; AccessoryColombia
-
Louisiana State University Health Sciences Center...Recruiting